Our study demonstrates the disproportionate disease burden of T2DM and aggressive disease progression with continued requirement of insulin therapy amongst younger children with T2D who are morbidly obese and at‐risk minorities. This evidence concerns the gene INS and type 2 diabetes mellitus.